Ranabir Sinha Roy - Concepedia

Author

Ranabir Sinha Roy

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Ranabir Sinha Roy

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Harvard University

About

Ranabir Sinha Roy is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.4K
2	Biochemistry	10	10	1.3K
3	Natural Sciences	8	8	332
4	Health Sciences	2	2	583
5	Engineering	1	1	85

Ranabir Sinha Roy

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
(2<i>R</i>)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-<i>a</i>]pyrazin- 7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes Dooseop Kim, Liping Wang, Maria Beconi, Journal of Medicinal Chemistry	2004	808
Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes George R. Lankas, Barbara Leiting, Ranabir Sinha Roy, Diabetes Diabetes ManagementPharmacological StudyBiochemistryDiabetesPharmacology	2005	490
Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes James Mu, John Woods, Yun-Ping Zhou, Diabetes Dipeptidyl Peptidase-4Insulin SignalingGastrointestinal Peptide HormoneObesityMetabolic Syndrome	2006	450
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Stacey Conarello, Zhihua Li, John Ronan, Proceedings of the National Academy of Sciences	2003	348
The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides Lan Zhu, Constantin Tamvakopoulos, Dan Xie, Journal of Biological Chemistry	2003	219
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes James Mu, Aleksandr Petrov, George J. Eiermann, European Journal of Pharmacology Metabolic SyndromeDiabetes ManagementMedicineDiabetesPhysiology	2009	133
(2<i>S</i>,3<i>S</i>)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-<i>N,N</i>-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-<i>a</i>]- pyridin-6-ylphenyl)butanamide: A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes Scott D. Edmondson, Anthony Mastracchio, Robert J. Mathvink, Journal of Medicinal Chemistry	2006	121
Cofactor Requirements and Reconstitution Of Microcin B17 Synthetase: A Multienzyme Complex that Catalyzes the Formation of Oxazoles and Thiazoles in the Antibiotic Microcin B17 Jill C. Milne, Ranabir Sinha Roy, Andrew C. Eliot, Biochemistry EngineeringChemical BiologyDiversity Oriented SynthesisBiosynthesisMicrocin B17 Synthetase	1999	85
Discovery of Potent and Selective Dipeptidyl Peptidase IV Inhibitors Derived from β-Aminoamides Bearing Subsituted Triazolopiperazines Dooseop Kim, Jennifer E. Kowalchick, Linda Brockunier, Journal of Medicinal Chemistry Molecular PharmacologyMedicinal ChemistryPharmaceutical SciencePharmaceutical ChemistryPharmacological Study	2008	60
Design and Synthesis of Prolylcarboxypeptidase (PrCP) Inhibitors To Validate PrCP As A Potential Target for Obesity Changyou Zhou, Margareta Garcia-Calvo, Shirly Pinto, Journal of Medicinal Chemistry	2010	51

Page 1